ATE410147T1 - Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd - Google Patents

Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd

Info

Publication number
ATE410147T1
ATE410147T1 AT03704789T AT03704789T ATE410147T1 AT E410147 T1 ATE410147 T1 AT E410147T1 AT 03704789 T AT03704789 T AT 03704789T AT 03704789 T AT03704789 T AT 03704789T AT E410147 T1 ATE410147 T1 AT E410147T1
Authority
AT
Austria
Prior art keywords
glycosamin
glycans
copd
heparin
respiratory diseases
Prior art date
Application number
AT03704789T
Other languages
English (en)
Inventor
Janis Kay Shute
Mary Patricia Carroll
Conway Joy H Dr
Peter Morey Hockey
Original Assignee
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27739233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE410147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0203773A external-priority patent/GB0203773D0/en
Priority claimed from GB0203830A external-priority patent/GB0203830D0/en
Priority claimed from GB0211414A external-priority patent/GB0211414D0/en
Priority claimed from GB0224330A external-priority patent/GB0224330D0/en
Application filed by Univ Southampton filed Critical Univ Southampton
Application granted granted Critical
Publication of ATE410147T1 publication Critical patent/ATE410147T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT03704789T 2002-02-18 2003-02-14 Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd ATE410147T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0203773A GB0203773D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0203830A GB0203830D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0211414A GB0211414D0 (en) 2002-05-17 2002-05-17 Treatment of respiratory disorders
GB0224330A GB0224330D0 (en) 2002-10-18 2002-10-18 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
ATE410147T1 true ATE410147T1 (de) 2008-10-15

Family

ID=27739233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03704789T ATE410147T1 (de) 2002-02-18 2003-02-14 Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd

Country Status (9)

Country Link
EP (1) EP1511466B2 (de)
AT (1) ATE410147T1 (de)
AU (1) AU2003207317A1 (de)
CA (1) CA2516318C (de)
DE (1) DE60323973D1 (de)
DK (1) DK1511466T4 (de)
ES (1) ES2315479T5 (de)
PT (1) PT1511466E (de)
WO (1) WO2003068187A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
AU2004278013B2 (en) 2003-10-01 2009-01-15 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
TW201306847A (zh) * 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
AU2019207288A1 (en) 2018-01-11 2020-08-13 Emphysema Solutions Bv Compositions and methods for the treatment of lung emphysema and other forms of COPD
US12329759B2 (en) 2019-10-17 2025-06-17 Trustees Of Boston University Methods and compositions relating to lung function
IT202100021602A1 (it) * 2021-08-09 2023-02-09 Sofar Spa Composizione in forma di polvere secca per inalazione per uso in un metodo di trattamento di un’infiammazione e/o di uno stress ossidativo dell’apparato respiratorio causata/o da inquinamento dell’aria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
US7709461B2 (en) * 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides

Also Published As

Publication number Publication date
PT1511466E (pt) 2009-01-16
DK1511466T3 (da) 2009-02-16
HK1074582A1 (en) 2005-11-18
ES2315479T3 (es) 2009-04-01
DK1511466T4 (en) 2015-03-30
CA2516318A1 (en) 2003-08-21
CA2516318C (en) 2011-07-19
DE60323973D1 (de) 2008-11-20
ES2315479T5 (es) 2015-07-01
EP1511466B2 (de) 2015-02-25
AU2003207317A1 (en) 2003-09-04
EP1511466A1 (de) 2005-03-09
EP1511466B1 (de) 2008-10-08
WO2003068187A1 (en) 2003-08-21

Similar Documents

Publication Publication Date Title
NO20073900L (no) Anvendelse av LGG for fremstilling av et medikament for forebygging eller behandling av respiratoriske sykdommer
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
TR200103233T2 (tr) Antikolinerjik etkili bileşik ve ß-mimetikler bazında yeni ilaç bileşimleri.
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
EA200500715A1 (ru) Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
ATE408601T1 (de) Fredericamycin-derivate
SE0301010D0 (sv) Novel compounds
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
SE9800836D0 (sv) New Compounds
ATE448232T1 (de) Substituierte heterozyklen
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
EA200500782A1 (ru) Лечение геморрагического шока
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
ATE402141T1 (de) Phenäthanolaminderivate zur behandlung von krankheiten der atemwege
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
MX2007003157A (es) 4-feniltetrahidroisoquinolinas sustituidas, metodo para su produccion, su uso como medicamento y un medicamento que las contiene.
PT1082321E (pt) Derivados heterociclicos que inibem o factor xa
IS2613B (is) Útskipt díketópíperasín sem oxýtósínblokkar
DE60323973D1 (de) Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
ATE526967T1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
EA200400399A1 (ru) Способы лечения легочных заболеваний
NO975028L (no) Piperazinoderivater som neurokininantagonister
EA200401305A1 (ru) Аэрозольная композиция для ингаляции, содержащая соль тиотропия

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1511466

Country of ref document: EP